Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure

PLoS ONE

Volumn 12, Issue 3, 2017, Pages

  Valbusa, Filippo ^a   Bonapace, Stefano ^a   Agnoletti, Davide ^a   Scala, Luca ^a   Grillo, Cristina ^a   Arduini, Pietro ^a   Turcato, Emanuela ^a   Mantovani, Alessandro ^b   Zoppini, Giacomo ^b   Arcaro, Guido ^a   Byrne, Christopher ^c,d   Targher, Giovanni ^b  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GAMMA GLUTAMYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SPIRONOLACTONE;

ACUTE HEART FAILURE; AGED; APRI INDEX; ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE EXACERBATION; DISEASE SEVERITY; ECHOGRAPHY; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FIB 4 SCORE; GASTROINTESTINAL DISEASE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL READMISSION; HUMAN; ISCHEMIC HEART DISEASE; ITALY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NAFLD FIBROSIS SCORE; NONALCOHOLIC FATTY LIVER; PROGNOSIS; RESPIRATORY TRACT DISEASE; ACUTE DISEASE; COHORT ANALYSIS; COMPLICATION; HEART FAILURE; RISK FACTOR; VERY ELDERLY;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HEART FAILURE; HUMANS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; PATIENT READMISSION; RISK FACTORS;

EID: 85015277580     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0173398     Document Type: Article

References (34)

1. van Riet EE, Hoes AW, Wagenaar KP, Limburg A, Landman MA, Rutten FH. Epidemiology of heart failure: the prevalence of heart failure and ventricular dysfunction in older adults over time. A systematic review. Eur J Heart Fail 2016; 18:242-252. https://doi.org/10.1002/ejhf.483 PMID: 26727047
2. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, et al; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14:803-869. https://doi.org/10.1093/eurjhf/hfs105 PMID: 22828712
3. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 2013; 61:391-403. https://doi.org/10.1016/j.jacc.2012.09.038 PMID: 23219302
4. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62:S47-S64. https://doi.org/10.1016/j.jhep.2014.12.012 PMID: 25920090
5. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363:1341-1350. https://doi.org/10.1056/NEJMra0912063 PMID: 20879883
6. Mantovani A, Ballestri S, Lonardo A, Targher G. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci 2016; 61:1246-1267. https://doi.org/10.1007/s10620-016-4040-6 PMID: 26809873
7. Dhingra R, Gona P, Wang TJ, Fox CS, D'Agostino RB, Vasan RS. Serum gamma-glutamyltransferase and risk of heart failure in the community. ArteriosclerThromb Vasc Biol 2010; 30:1855-1860. https://doi.org/10.1161/ATVBAHA.110.207340 PMID: 20539015
8. Wannamethee SG, Whincup PH, Shaper AG, Lennon L, Sattar N. Gamma-glutamyltransferase, hepatic enzymes, and risk of incident heart failure in older men. Arterioscler Thromb Vasc Biol 2012; 32:830-835. https://doi.org/10.1161/ATVBAHA.111.240457 PMID: 22223732
9. Wang Y, Tuomilehto J, Jousilahti P, Salomaa V, Li B, Mähönen M, et al. Serum v-glutamyltransferase and the risk of heart failure in men and women in Finland. Heart 2013; 99:163-167. https://doi.org/10.1136/heartjnl-2012-302972 PMID: 23144292
10. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 2015; 62:773-783. https://doi.org/10.1002/hep.27869 PMID: 25914296
11. Valbusa F, Bonapace S, Grillo C, Scala L, Chiampan A, Rossi A, et al. Nonalcoholic fatty liver disease is associated with higher 1-year all-cause rehospitalization rates in patients admitted for acute heart failure. Medicine (Baltimore) 2016; 95:e2760.
12. McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol 2016 Oct 11. [Epub ahead of print].
13. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150:604-612. PMID: 19414839
14. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54:1082-1090. https://doi.org/10.1002/hep.24452 PMID: 21618575
15. Ballestri S, Romagnoli D, Nascimbeni F, Francica G, Lonardo A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev Gastroenterol Hepatol 2015; 9:603-627. https://doi.org/10.1586/17474124.2015.1007955 PMID: 25694178
16. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al; American Society of Echocardiography's Nomenclature and Standards Committee; Task Force on Chamber Quantification; American College of Cardiology Echocardiography Committee; American Heart Association; European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7:79-108. https://doi.org/10.1016/j.euje.2005.12.014 PMID: 16458610
17. Kociol RD, Horton JR, Fonarow GC, Reyes EM, Shaw LK, O'Connor CM, et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. Circ Heart Fail 2011; 4:628-636. https://doi.org/10.1161/CIRCHEARTFAILURE.111.962290 PMID: 21743005
18. Targher G, Dauriz M, Tavazzi L, Temporelli PL, Lucci D, Urso R, et al; IN-HF Outcome Investigators. Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: Results of the IN-HF (Italian Network on Heart Failure) Outcome registry. Int J Cardiol 2016; 203:587-593. https://doi.org/10.1016/j.ijcard.2015.10.207 PMID: 26574932
19. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al; ESC-HFA HF Long-Term Registry investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 2017; 19:54-65. https://doi.org/10.1002/ejhf.679 PMID: 27790816
20. Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, Hill SA, et al. BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev 2014; 19:453-470. https://doi.org/10.1007/s10741-014-9442-y PMID: 25062653
21. Poelzl G, Eberl C, Achrainer H, Doerler J, Pachinger O, Frick M, et al. Prevalence and prognostic significance of elevated gamma-glutamyltransferase in chronic heart failure. Circ Heart Fail 2009; 2:294-302. https://doi.org/10.1161/CIRCHEARTFAILURE.108.826735 PMID: 19808352
22. Alvarez AM, Mukherjee D. Liver abnormalities in cardiac diseases and heart failure. Int J Angiol 2011; 20:135-142. https://doi.org/10.1055/s-0031-1284434 PMID: 22942628
23. Siegelman ES, Rosen MA. Imaging of hepatic steatosis. Semin Liver Dis 2001; 21:71-80. PMID: 11296698
24. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 2015; 47:997-1006. https://doi.org/10.1016/j.dld.2015.08.004 PMID: 26454786
25. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2016; 65:589-600. https://doi.org/10.1016/j.jhep.2016.05.013 PMID: 27212244
26. Granér M, Nyman K, Siren R, Pentikäinen MO, Lundbom J, Hakkarainen A, et al. Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging 2015; 8:e001979. https://doi.org/10.1161/CIRCIMAGING.114.001979 PMID: 25550397
27. Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, et al. Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci (Lond) 2013; 125:301-309.
28. Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, et al. Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS One 2013; 8:e57183. https://doi.org/10.1371/journal.pone.0057183 PMID: 23451184
29. Käräjämäki AJ, Pätsi OP, Savolainen M, Kesäniemi YA, Huikuri H, Ukkola O. Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA Study). PLoS One 2015; 10:e0142937. https://doi.org/10.1371/journal.pone.0142937 PMID: 26571029
30. Alonso A, Misialek JR, Amiin MA, Hoogeveen RC, Chen LY, Agarwal SK, et al. Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 2014; 100:1511-1516. https://doi.org/10.1136/heartjnl-2014-305756 PMID: 24924619
31. Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, et al. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22:9674-9693. https://doi.org/10.3748/wjg.v22.i44.9674 PMID: 27956792
32. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). Diabetologia 2016; 59:1121-1140. https://doi.org/10.1007/s00125-016-3902-y PMID: 27053230
33. Byrne CD, Targher G. Time to replace assessment of liver histology with MR-based imaging tests to assess efficacy of interventions for nonalcoholic fatty liver disease. Gastroenterology 2016; 150:7-10. https://doi.org/10.1053/j.gastro.2015.11.016 PMID: 26602219
34. Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, et al. Magnetic resonance elastography vs. transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease. Gastroenterology 2017; 152:598-607. https://doi.org/10.1053/j.gastro.2016.10.026 PMID: 27911262